US Dollar vs MXN

Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

Regístrate

KURA Kura Oncology Inc

15.91

0.00 (0.00%)

Pre Mercado

Última actualización: 03:01:22

Retrasado por 15 minutos

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

11/18/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

06/10/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ UBS Financial Services Inc, as attorney-in-fact for Kathleen Ford

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Kura Oncology (NASDAQ:KURA)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024

Haga Click aquí para más Gráficas Kura Oncology.

Kura Oncology (NASDAQ:KURA)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024

Haga Click aquí para más Gráficas Kura Oncology.

Noticias sobre Kura Oncology Inc KURA

Form 8-K - Current report
Miércoles 20 de Noviembre 2024 (11 horas hace) • Edgar (US Regulatory)

Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
Miércoles 20 de Noviembre 2024 (11 horas hace) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Martes 19 de Noviembre 2024 (2 días hace) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Lunes 18 de Noviembre 2024 (3 días hace) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Jueves 7 de Noviembre 2024 (2 semanas hace) • Edgar (US Regulatory)

Form 8-K - Current report
Jueves 7 de Noviembre 2024 (2 semanas hace) • Edgar (US Regulatory)

Kura Oncology Reports Third Quarter 2024 Financial Results
Jueves 7 de Noviembre 2024 (2 semanas hace) • GlobeNewswire Inc.

Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting
Martes 5 de Noviembre 2024 (2 semanas hace) • GlobeNewswire Inc.

Kura Oncology to Report Third Quarter 2024 Financial Results
Jueves 31 de Octubre 2024 (3 semanas hace) • GlobeNewswire Inc.

Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)
Jueves 24 de Octubre 2024 (4 semanas hace) • GlobeNewswire Inc.

Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors
Miércoles 23 de Octubre 2024 (4 semanas hace) • GlobeNewswire Inc.

Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology
Lunes 30 de Septiembre 2024 (2 meses hace) • GlobeNewswire Inc.

Más de Kura Oncology Inc Artículos de Noticias

Gold vs US Dollar

JP Morgan Chase

Deutsche Telekom (QX)

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones